Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's Leqembi (lecanemab-irmb) for maintenance dosing once every four weeks ...
Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...
Eisai makes it clear that the intention is in part to help support the rollout of Biogen-partnered Leqembi (lecanemab), the first disease-modifying treatment for Alzheimer’s disease, which was ...
Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
13don MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Over the weekend, the Food and Drug Administration approved Leqembi, the Alzheimer’s treatment from Eisai and Biogen, for monthly dosing maintenance after patients use it biweekly for 18 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results